https://immattersacp.org/weekly/archives/2024/06/11/3.htm

MKSAP Quiz: Polyuria, nocturia for 6 weeks

A 38-year-old woman seeks treatment for polyuria and nocturia that began 6 weeks ago after starting lithium for bipolar disorder. Medical history is otherwise unremarkable. Her only other medication is olanzapine. Following a physical exam and lab studies, what is the most appropriate management?


A 38-year-old woman seeks treatment for polyuria and nocturia that began 6 weeks ago after starting lithium for bipolar disorder. Medical history is otherwise unremarkable. Her only other medication is olanzapine.

Physical examination findings, including vital signs, are normal.

Laboratory studies show a serum sodium level of 145 mEq/L (145 mmol/L) and a urine osmolality of 200 mOsm/kg H2O.

Which of the following is the most appropriate management?

A. Add amiloride
B. Add furosemide
C. Decrease water intake
D. Increase protein intake

Reveal the Answer

MKSAP Answer and Critique

The correct answer is A. Add amiloride. This content is available to MKSAP 19 subscribers as Question 40 in the Nephrology section. More information about MKSAP is available online.

The most appropriate management is to add amiloride (Option A). This patient has polyuria, a serum sodium concentration at the upper limit of normal, and dilute urine, which establish the diagnosis of arginine vasopressin deficiency (formerly central diabetes insipidus) or arginine vasopressin resistance (formerly nephrogenic diabetes insipidus). Arginine vasopressin deficiency may be secondary to an inadequate release of antidiuretic hormone (ADH) and arginine vasopressin resistance may be secondary to inadequate action of ADH. Arginine vasopressin deficiency can result from tumors that invade the hypothalamus, infiltrating diseases such as sarcoidosis, or surgical destruction. Arginine vasopressin resistance is often caused by drugs such as lithium. The temporal association with the initiation of lithium in this patient establishes the diagnosis of lithium-induced arginine vasopressin resistance. Up to 40% of patients treated with lithium will develop polydipsia secondary to lithium interfering with the action of ADH. Amiloride is the most appropriate management in this case, as it blocks the epithelial sodium channel in the collecting tubule and prevents the uptake of lithium by these cells. Intracellular lithium appears to decrease the number of aquaporin water channels inserted in the membrane, thereby decreasing water reabsorption causing increased excretion of dilute urine. If amiloride is ineffective and lithium must be continued, the treatment of arginine vasopressin resistance is aimed at decreasing the amount of urine excreted and is best accomplished by limiting solute intake and causing mild volume depletion with the use of a thiazide diuretic. Because the amount of urine excreted daily is dependent on solute intake and minimum urine osmolality, decreasing solute will limit urine volume. By causing mild volume depletion with a thiazide diuretic, more salt and water will be reabsorbed in the proximal tubule and loop of Henle, further decreasing urine output.

Although furosemide (Option B) will produce volume depletion, it is not helpful in the treatment of arginine vasopressin resistance. Furosemide blocks the ability to concentrate the urine at the loop of Henle, creating a state of antidiuretic hormone resistance.

Patients with arginine vasopressin resistance will develop increased thirst as their serum sodium increases. Water intake should never be restricted (Option C) in patients with nephrogenic DI because it can lead to severe hypernatremia.

Because the treatment of arginine vasopressin resistance is aimed at decreasing solute intake, increasing protein intake (Option D) is not appropriate management.

Key Points

  • Treatment of lithium-induced arginine vasopressin resistance is best accomplished with amiloride, as it blocks the epithelial sodium channel in the collecting tubule and prevents the uptake of lithium by these cells.
  • If amiloride is ineffective in treating lithium-induced arginine vasopressin resistance and lithium must be continued, treatment is aimed at limiting solute intake and causing mild volume depletion with the use of a thiazide diuretic.